Novel aspects of mevalonate pathway inhibitors as antitumor agents

Area of Science:

• Oncology
• Biochemistry
• Immunology

Background:

• The mevalonate pathway is crucial for cholesterol biosynthesis and protein prenylation, processes linked to cancer development.
• Mutant p53, common in cancers, upregulates mevalonate metabolism and protein prenylation.
• Statins and bisphosphonates inhibit mevalonate metabolism and have been explored as anticancer agents.

Purpose of the Study:

• To review the novel anticancer capabilities of mevalonate pathway inhibitors.
• To explore their potential to reverse malignant phenotypes and enhance tumor immune surveillance.

Main Methods:

• Review of existing literature on mevalonate pathway inhibitors, statins, bisphosphonates, and their effects on tumor biology.
• Analysis of the role of mutant p53 in regulating the mevalonate pathway.
• Investigation of drug-induced cellular stress responses and immune activation.

Main Results:

• Mevalonate pathway inhibitors demonstrate potential in reversing the malignant phenotype.
• Inhibitors can induce cellular stress responses like unfolded protein response and autophagy.
• These responses lead to inflammasome-dependent, caspase-1-mediated innate immunity activation.

Conclusions:

• Mevalonate pathway inhibitors possess novel properties beneficial for tumor biology.
• Their immunomodulatory effects contribute to anticancer activity and tumor immune surveillance.
• Targeting the mevalonate pathway offers a promising strategy for cancer therapy.